Endometrial cancer is the most common gynecological malignancy in well-developed countries. Biologically and clinicopathologically, endometrial carcinomas are divided into two types: type 1 or estrogen-dependent carcinomas and type 2 or estrogen-independent carcinomas. Type 1 cancers correspond mainly to endometrioid carcinomas and account for approximately 90 % of endometrial cancers, whereas type 2 cancers correspond to the majority of the other histopathological subtypes.
1
Endometrial Cancer: Background
Epidemiology
Endometrial cancer is the fifth most common malignancy in females worldwide, after breast, colorectal, cervical, and lung cancers, accounting for 4.8 % of all cancers in women (Ferlay et al. 2013) . In contrast to cervical cancer, endometrioid cancer peak incidence rates occur in well-developed countries (Europe and North America), where it is the most common gynecological malignancy (Ferlay et al. 2013) . This is probably due to lifestyle factors, in particular obesity, which has been linked to about 50 % endometrial cancers in these countries (Epstein and Blomqvist 2014; Calle and Kaaks 2004) . The increase in life expectancy is also responsible for its rising (Koh et al. 2014) .
Endometrial cancer is more likely to occur in postmenopausal women in their sixth and seventh decades, with cases only rarely reported under the age of 35 in the United Kingdom (Patel et al. 2010; Cancer Incidence Statistics 2015) .
Despite its relatively high prevalence, approximately 82 % of endometrial cancers are diagnosed at an early stage, which makes its overall prognosis favorable (Cancer Incidence Statistics 2015) . Its worldwide mortality rate is low and it has been estimated at 2.2 % (Ferlay et al. 2013 ).
Pathology and Risk Factors
The World Health Organization (WHO) classification of uterine corpus tumors was revised in 2014 (Kurman et al. 2014) . Endometrial carcinomas (also known as adenocarcinoma of the endometrium) are classified under the "Epithelial Tumours and Precursors" group and clinicopathologically divided into the following types: endometrioid carcinoma; mucinous carcinoma; serous endometrial intraepithelial carcinoma; serous carcinoma; clear-cell carcinoma; neuroendocrine tumors; mixed cell adenocarcinoma; undifferentiated carcinoma; and dedifferentiated carcinoma (Table 1 ) (Kurman et al. 2014) . Although carcinosarcoma belongs to the "Mixed Epithelial and Mesenchymal Tumours" group of the uterine corpus, it should be staged as an endometrial carcinoma (Kurman et al. 2014) .
Biologically and clinicopathologically, endometrial carcinomas are divided into two types: type 1 or estrogen-dependent carcinomas and type 2 or estrogen-independent carcinomas (Table 2) .
Type 1 correspond mainly to endometrioid carcinomas and accounts for approximately 90 % of endometrial cancers, whereas type 2 cancers correspond to the majority of the other histopathological subtypes (Epstein and Blomqvist 2014) .
Type 1 endometrial cancers are associated with prolonged unopposed estrogen exposure, therefore with the following risk factors: estrogen replacement therapy; tamoxifen therapy for breast cancer; polycystic ovarian syndrome; estrogen producing ovarian tumors; obesity (conversion of androgen to estrone in adipose tissue); diabetes; early menarche and late menopause and nulliparity (Shapiro et al. 1985; Fisher et al. 1994; Renehan et al. 2008; Soliman et al. 2006; McPherson et al. 1996) .
Endometrioid cancers are endometrial glandular neoplasms that can be preceded or associated Kurman et al. (2014) with endometrial hyperplasia (Kurman et al. 2014; Colombo et al. 2013) . They are subdivided into three grades of differentiation (well to poorly differentiated) according to the amount of solid components (Colombo et al. 2013; Tirumani et al. 2013) . Low-grade tumors are usually diagnosed at an early stage and generally have a good outcome, whereas high-grade endometrioid cancers are associated with a poor prognosis .
Endometrioid cancers are characteristically associated with PTEN, K-RAS, and CTNNB gene mutations .
Mucinous carcinomas are a rare form of type 1 endometrial cancer, where more than 50 % of glandular cells mucin can be found. They are in the majority of times well differentiated and associated with good prognosis (Kurman et al. 2014; Jalloul et al. 2012) .
Type 2 tumors are constituted by the other histological types, namely, serous carcinoma and clear-cell carcinoma Jalloul et al. 2012) . They have a more aggressive clinical behavior, a poorer prognosis, and are usually diagnosed at higher stage Jalloul et al. 2012) .
Genetics changes such as p53 and p16 inactivation genes and gene overexpression of HER-2/neu are frequently present in these types of carcinomas Hecht and Mutter 2006) .
Although classically considered estrogenindependent cancers, Setiawan and her colleagues found an overlap between risk factors of type 1 and type 2 endometrial cancers (Setiawan et al. 2013) . Parity, oral contraceptives use, age at menarche, diabetes and smoking were associated with both type 2 (mainly serosal and mixed carcinomas) and type 1 cancers (Setiawan et al. 2013) . The risk factors of type 2 endometrial cancer and high-grade endometrioid tumors were similar, whereas body mass index was more associated with type 1 cancer (Setiawan et al. 2013) .
Serous carcinomas make up the majority of type 2 endometrial cancers. They are characterized by the presence of complex papillary architecture associated with remarkable nuclear pleomorphism (Kurman et al. 2014 ). They are not associated with endometrial hyperplasia, but may be preceded by serous endometrial intraepithelial carcinoma, a noninvasive form of carcinoma confined to the epithelium that generally develops in a polyp or in an atrophic endometrium (Kurman et al. 2014) .
Clear-cell carcinoma is a rare form of type 2 cancer that resembles its ovarian counterpart (Kurman et al. 2014) .
Undifferentiated and dedifferentiated carcinomas of the endometrium are also rare types. The former is characterized by the presence of cells with no differentiation, whereas the latter is composed partially by undifferentiated type carcinoma and by International Federation of Gynaecology Obstetrics (FIGO) grade 1 or 2 endometrioid carcinoma (Kurman et al. 2014) .
Mixed carcinomas are made of two or more types of endometrial carcinomas, with at least one being a type 2 carcinoma (Kurman et al. 2014) .
Neuroendocrine tumors of the endometrium are extremely rare tumors. (Kurman et al. 2014) .
Endometrial neuroendocrine tumors may be of low grade (carcinoid tumors) or of high grade (small cell neuroendocrine carcinomas and large cell neuroendocrine tumors).
The majority of cases reported in the literature are of small cell neuroendocrine carcinomas, which present as their lung counterpart (Lopes Dias et al. 2015) .
They tend to be aggressive tumors with a poor prognosis. Women are generally in the postmenopausal age and tend to present with vaginal bleeding, but sometimes due to their aggressiveness, metastatic pain can be present (Lopes Dias et al. 2015; Eichhorn and Young 2001) .
Carcinosarcomas are an admixture of carcinomatous and mesenchymal sarcomatous components (Kurman et al. 2014) . Carcinomatous elements are generally high-grade endometrioid, serous, clear-cell, or undifferentiated carcinomas. Carcinosarcomas are classified under the "Mixed epithelial and mesenchymal" group (Kurman et al. 2014 ). However, due to their carcinomatous component and to the fact that their risk factors present symptoms and behavior similar to those of high-grade endometrial carcinomas, they are staged as such.
The radiological and pathological appearances of these tumors tend to differ from the other histopathological endometrial cancer subtypes, as they tend to present as large hemorrhagic and necrotic masses that distend the endometrial cavity, compressing and frequently invading the myometrium and the cervical stroma. Their prognosis is poor since they tend to present lymphatic and sometimes hematogenous spread at the time of diagnosis. Recurrence is also frequent.
The majority of endometrial cancers are sporadic. Nonetheless, about 5 % of endometrial cancers are caused by genetic mutations (e.g., Lynch syndrome, Cowden syndrome). These cancers tend to occur 10-20 years before the sporadic type (Koh et al. 2014; Resnick et al. 2009 ).
Symptoms and Diagnosis
About 90 % of patients with endometrial carcinoma present with abnormal vaginal bleeding (Koh et al. 2014; Colombo et al. 2013) . Therefore, endometrial carcinoma is often diagnosed at an early and treatable stage, at which the prognosis is good. Some women also seek care owing to pelvic pain or pressure (usually patients with advanced stage disease). Moreover, patients may present with atypical glandular cells on cervical cytology, which requires further evaluation for premalignant or malignant diseases of the endocervix and of the endometrium.
The first diagnostic step to evaluate women with pre-and postmenopausal abnormal vaginal bleeding should be the measurement of endometrial thickness with transvaginal ultrasound (TVUS) (Fig. 1) (Bennet et al. 2011) . Transabdominal ultrasound may also be used as an adjunct modality, particularly in large leiomyomatous uterus or when women cannot tolerate TVUS (Bennet et al. 2011) .
In postmenopausal women with vaginal bleeding an upper threshold of 5 mm or of 4 mm for normal endometrial thickness should be considered (Bennet et al. 2011; Gull et al. 2003; Karlsson et al. 1995; Smith-Bindman et al. 1998) . In this age group, an endometrial thickness measurement ≤5 mm is associated with the absence of endometrial cancer (Gupta et al. 2002) . This cut-off value should also be used in women under hormone replacement therapy and under tamoxifen (Bennet et al. 2011) .
In symptomatic patients in premenopausal age, an upper threshold of normal endometrial thickness is more difficult to establish due to its variations during the menstrual cycle. In this group of women, the assessment of the endometrium should be performed during the early first half of the menstrual cycle (Bennet et al. 2011) . In these women, an endometrial thickness >16 mm has shown to have a sensitivity of 67 % and a specificity of 75 % for detecting endometrial abnormalities (Bennet et al. 2011; Hulka et al. 1994) . A heterogeneous endometrium or an area of focal thickness should be also further investigated (Bennet et al. 2011; Goldstein et al. 2001) .
If the endometrium is thickened or heterogeneous, a sample of the endometrium must be undertaken to establish a definite histopathological diagnosis. In these cases a hysteroscopy with biopsy or resection should be performed.
Before treatment, the initial evaluation should include a medical history, a physical and gynecological examination, a complete blood count, and a chest radiograph (Koh et al. 2014) .
If the age of the onset of the disease is <50 years and if there is history of familiar colorectal or endometrial cancer, screening for genetic mutations should be performed (Koh et al. 2014) .
Women with Lynch syndrome, without endometrial cancer, should be screened annually with an endometrial biopsy (Koh et al. 2014; Järvinen et al. 2009; Meyer et al. 2009 ). Prophylactic hysterectomy with bilateral salpingoophorectomy may be considered in these patients (Koh et al. 2014; Schmeler et al. 2006 ).
Endometrial Cancer Staging
Endometrial carcinoma is staged with the International Federation of Gynaecology Obstetrics (FIGO) system, which was last revised in 2009 (Table 3 ) (Creasman 2009; Pecorelli 2009 ). This classification defines that endometrial carcinoma is staged on the basis of surgicopathological findings. The complete surgical staging procedure implies hysterectomy with bilateral salpingooophorectomy, assessment of the abdominal cavity with biopsies of suspicious peritoneal lesions, cytology of peritoneal washings, and pelvic and retroperitoneal lymphadenectomy (Koh et al. 2014) . In patients with serous carcinoma, clearcell carcinoma, and carcinosarcoma, the surgical staging procedure should be the same as for ovarian cancer (Koh et al. 2014) .
The FIGO 2009 staging classification is as follows (Table 3) (Pecorelli 2009): In stage I, the tumor is confined to the uterus. This stage is subdivided in two substages: stage IA (the tumor invades <50 % of the myometrium) and stage IB (the tumor invades ≥50 % of the myometrium). In stage II, the tumor invades the cervical stroma, but not beyond the uterus.
Stage III is subdivided into three substages. In stage IIIA, the tumor invades the serosa or/and the adnexa (direct extension or metastasis). In stage IIIB, there is involvement of the parametria and/or the vagina (direct extension or metastasis). In stage IIIC, there is lymph node involvement (III C1 if there are positive pelvic lymph nodes and III C2 if there are positive para-aortic lymph nodes).
Stage IV is also subdivided into two substages. The tumor is in stage IVA if there is mucosal invasion of the bladder or/and the bowel and it is in stage IVB if there are distant metastasis including abdominal metastasis and/or the presence of positive inguinal lymph nodes.
MR imaging is not considered in the FIGO staging of endometrial carcinoma, but due to its high contrast resolution and reproducibility, it has an important role in the preoperative staging of the disease. Thus, it is crucial for tailoring the surgical approach to these patients.
There is still no consensus on whether complete surgical staging with primary pelvic and para-aortic lymphadenopathy should be performed at stage I, namely, in patients with low recurrence risk (Bonatti et al. 2015; Todo et al. 2010; May et al. 2010 ). However, it is known that the tumor histological type and grade, the presence of myometrial invasion ≥50 %, and the presence of lymphovascular space invasion correlate with the presence of lymph node metastasis and with overall survival (Rechichi et al. 2010; Sala et al. 2013; Boronow 1990; Larson et al. 1996) . From these features, only the histological type and grade can be assessed preoperatively without imaging. Nonetheless, discrepancies of up to 15 % between the pre-and postoperative tumoral histopathological results have been described Frei et al. 2000) .
MR can accurately determine the depth of myometrial invasion. Therefore, in conjunction with the histopathological grade it may be used to select the patients that might be candidates for pelvic and para-aortic lymphadenectomy, precluding surgery in low-risk patients, thus avoiding the morbidities associated with this procedure.
Presence of lymph node metastases has been reported in more than 30 % of the cases of endometrial cancer with ≥50 % of myometrial invasion and in only 5 % of cases when the tumor invades <50 % of the myometrium (Larson et al. 1996; Gallego et al. 2014) .
Lymphovascular invasion is generally assessed postoperatively. It is related not only to the likelihood of lymph node involvement, but with tumor relapse and poor survival Fujii et al. 2015; Briët et al. 2005) . Not many studies have addressed the role of MR in diagnosing lymphovascular space involvement. However, a study by Nougaret et al. showed that whole tumor volume and ADC could be useful in its prediction (Nougaret et al. 2015) .
Cervical stromal invasion is also associated with lymph node metastasis and poor survival. MR can accurately diagnose cervical stromal invasion and parametrial invasion. This is particularly important so surgeons can avoid cutting through the tumor and thus perform an extensive resection .
Moreover, MR is helpful is diagnosing advanced disease involving the adnexa and the peritoneum, which generally are contraindications to laparoscopic and robotic surgery Venkat et al. 2012; Amant et al. 2007 ). Other extra-uterine coexistent pathologies can also be diagnosed that may help determining the surgical approach.
Therefore, MR is useful not only in planning surgical treatment but also in selecting more advanced and difficult surgical cases that should be guided to specialized oncologic centers.
MR is also useful in determining the origin (cervical or endometrial) of a biopsy proven adenocarcinoma (Fig. 2 ). Vargas and colleagues showed that by assessing the epicenter of the tumor, the endometrial versus the cervical origin of an adenocarcinoma could be determined with an accuracy of 85-88 % (Vargas et al. 2011) . Furthermore, endometrial thickening, expansion of the endometrial cavity by a mass, and the presence of a tumor invading the myometrium may aid the discrimination between these two types of tumors (Haider et al. 2006 ). This distinction is particularly important, because early stage cervical adenocarcinomas are treated with surgery, advanced stage cervical adenocarcinomas are treated with chemotherapy and radiotherapy and endometrial carcinomas are treated primarily with surgery.
Although fertility-sparing progesterone therapy is not the standard of care for endometrial cancers, it might be considered according to patients request in treatment of low-grade endometrial cancers that do not invade the myometrium. In these cases, MR is essential in defining which patients are candidates to this approach.
MR Protocol for Staging Endometrial Carcinoma
In our institution the MR protocol for staging endometrial carcinoma is as follows (Table 4) : Patients are advised to fast 4-6 h before the procedure. A fast acting laxative enema to clean the bowel is administered the day before the exam and during the morning of the exam. Patients are encouraged to void before the examination since a full bladder degrades the quality of T2-weighted images.
In order to reduce bowel peristalsis and hence improve image quality, 1 mg of glucagon intravenous is administered before the exam. Alternatively, 20 mg or 40 mg of hyoscine butylbromide intramuscular/intravenous can be administered.
Patients are advised to avoid the use of vaginal tampon.
MR imaging can either be performed in a 1.5 T or a 3 T MR machine. 3 T MR has been not shown to offer significant benefit over 1.5 T MR in the evaluation of endometrial cancer, since 3 T MR is more prone to susceptibility and chemicalshift artifacts that impair the image quality (Wakefield et al. 2013; Haldorsen and Salvesen 2012; Hori et al. 2013) . A pelvic phase array is used along with anterior and superior saturation bands.
The patient should be placed in a supine position for the whole exam. However, prone position may be used in uncooperative patients.
Axial imaging of the abdomen (from diaphragm to iliac crests) should be performed for the evaluation of advanced disease, with fast recovery, fast spin-echo T2-weighted images (6 mm/1 mm, breath-hold). Abdominal axial diffusion-weighted images (DWI) (6 mm, b-values-0, 500, 1000 s/mm 2 ) and the respective ADC maps should also be obtained.
Evaluation of the pelvis should be performed with axial fast spin-echo T1-weighted images (5 mm/0.5 mm), axial fast spin-echo T2-weighted images (5 mm/0.5 mm), and sagittal fast spinecho T2-weighted images (4 mm/0.4 mm).
Fast spin-echo T2-weighted axial oblique images (perpendicular to the uterine cavity, 4 mm/0.4 mm) are helpful in assessing myometrial invasion (Fig. 3) . The dynamic contrast-enhanced MR images are obtained after the injection of 0.1 mmol/kg of gadolinium at a rate of 2 mL/s. In our institution, images are acquired using a 3D-recalled echo fatsuppressed T1-weighted sequence, pre-and postcontrast injection during five acquisition phases in the axial-oblique plane (perpendicular to the uterine cavity), until 150 s (2 mm). The dynamic study tends to be avoided in patients with renal impairment.
DWI study (b-values-0, 600, 1000 s/mm 2 , 5 mm/0.5 mm) and the respective ADC maps are performed in the axial plane.
If there is suspicion of cervix invasion, axial oblique of the cervix fast spin-echo T2-weighted images (perpendicular to the cervical canal, 4 mm/0.4 mm) are obtained to evaluate parametrial invasion (Fig. 3) . In these cases, the dynamic study should be performed in the sagittal plane using a 3D-reccaled echo fat-suppressed T1-weighted sequence, pre-and postcontrast injection during five acquisition phases until 150 s (2 mm). Furthermore, axial oblique of the cervix (perpendicular to cervical canal) postcontrast injection 3D-reccaled echo fat-suppressed T1-weighted images are obtained in a late phase (4 min, 2 mm), to better assess cervical stromal invasion (Fig. 3 ).
MR Findings According to the Stage of Endometrial Carcinoma
On conventional imaging, the normal uterus anatomy is better depicted on T2-weighted images. The endometrium tends to be hyperintense, the junctional zone is hypointense and the outer myometrium shows intermediate intensity (Fig. 4) . Endometrial cancer is isointense to the endometrium on T1-weighted images and it most frequently shows heterogeneous moderate to high-signal intensity on T2-weighted images. However, it can also show low-signal intensity on T2-weighted images (Fig. 5) .
On DCE-MR, in the arterial phase (≈30 s) endometrial tumors enhance earlier than does the normal endometrium, as this is the most adequate sequence to depict small endometrial tumors confined to the endometrium. At the equilibrium phase (≈120-180 s), tumors tend to be hypointense relative to the myometrium. However, they can remain isointense and a minority can even be hyperintense (Figs. 5 and 6 ).
On DWI-MR the tumors usually show restricted diffusion (hyperintensity on high b-value sequences and hypointensity on the respective ADC map) (Fig. 6) . ADC values have shown to be significantly lower in endometrial carcinoma than in normal endometrium and benign conditions such as endometrial polyps and submucosal leiomyomas (Fujii et al. 2008; Tamai et al. 2007; Takeuchi et al. 2009; Rechichi et al. 2011) (Fig. 7) .Therefore, this functional sequence can be helpful in diagnosing an endometrial tumor when biopsy cannot be easily performed (i.e., in the case of cervical stenosis) or when the histopathological diagnosis is not conclusive. Cross-reference with conventional sequences is, however, mandatory to avoid pitfalls, since restricted diffusion may be present also in retained secretions in the endometrial cavity.
Several studies have shown that there is no relation between the tumor grade, aggressiveness, and ADC values (Rechichi et al. 2011 ; Bharwani et al. 2011) . However, in one study higher grade tumors were associated with lower ADC values but there was a considerable overlap in estimation of histological grade based on ADC values ). Moreover, high ADC values may be found in high-grade tumors with a large necrotic component (Sala et al. 2010 ). tumor only invades <50 % of the myometrium, and stage IB disease, if the tumor invades ≥50 % of the myometrium (Figs. 8 and 9) (Pecorelli 2009) . If the patient is considering fertility-sparing treatment, it is also important to clearly define if the tumor is confined to the endometrium or if it invades the superficial myometrium, which precludes this approach ( Fig. 10 ) (Jafari Shobeiri et al. 2013; Kesterson and Fanning 2012) . T2-weighted images are useful in determining myometrial invasion. A focal or diffuse thickening of the endometrium with a clearly visualized intact junctional zone is a sign that the tumor is confined to the endometrium (Fig. 8) . Breaching and irregularity of the hypointense signal of the junctional zone implies superficial myometrial invasion (Manfredi et al. 2005) .
Stage I Disease
The depth of myometrial invasion should be based on the thickness of remaining myometrium where the tumor is at its deepest point into the myometrium (Haldorsen and Salvesen 2012; Koyama et al. 2007 ).
However, there are situations where the evaluation of myometrial invasion by T2-weighted images may be difficult or even impossible, such as the presence of: a tumor in the cornua (Fig. 11) ; a fibromatous uterus (Fig. 11) ; a less conspicuous junctional zone in postmenopausal women (Fig.  12) ; a thinned myometrium in postmenopausal women (Fig. 13) ; an adenomyotic uterus (Fig. 14) ; a polypoid uterus; a congenital abnormality (Fig.  15) ; and the presence of poor tumor signal difference/isointensity between the tumor and the myometrium (Figs. 6 and 16) (Kinkel 2006; Scoutt et al. 1995; Yamashita et al. 1993a; Saez et al. 2000; Fanning et al. 1990 ). In these cases, DCE-MR and DWI-MR play an important role, when combined with T2-weighted images. On DCE-MR imaging, in the arterial phase (≈ 30 s), the junctional zone typically enhances avidly when compared to the endometrial tumor (Manfredi et al. 2005) . Disruption of this subendometrial enhancement usually indicates myometrial invasion (Fujii et al. 2015; Manfredi et al. 2005; Nakao et al. 2006; Yamashita et al. 1993b; Kaneda et al. 2011; Frei and Kinker 2001) . This is particularly important when the patient is being considered for fertility-sparing treatment since the FIGO 2009 division of stage I disease is only based on the presence of invasion of the inner or outer portions of the myometrium (Fig. 10 ) (Jafari Shobeiri et al. 2013; Kesterson and Fanning 2012) .
On the other hand, it is in the equilibrium phase (≈120 s) that is better diagnosed deep myometrial invasion. In this phase there is more pronounced contrast-to-noise ratio between the outer myometrium, which is markedly hyperintense, and the endometrial tumor, which is usually hypointense (Figs. 9, 13 and 15) (Manfredi et al. 2005) . Attention must be paid to the presence of peritumoral inflammatory enhancement, which can exaggerate the appearance of myometrial invasion ).
DWI-MR has shown to be very useful in assessing myometrial invasion, especially in patients who cannot receive intravenous contrast, in patients with isointense or hyperintense tumors relative to the myometrium following contrast administration, and in patients with adenomyosis (Figs. 16, 14 and 16) (Takeuchi et al. 2009; Sala et al. 2010) .
Moreover, DWI-MR is very accurate in assessing myometrial invasion. Recent studies have shown that DWI-MR is significantly superior in the assessment of myometrial invasion when compared to DCE-MR (Bonatti et al. 2015; Rechichi et al. 2010; Takeuchi et al. 2009; Beddy et al. 2012) .
A prospective study conducted by Rechichi et al. has concluded that DWI-MR is highly accurate in assessing the depth of myometrial invasion and perhaps it could replace DCE-MR as a complement to T2-weighted images in the preoperative evaluation of endometrial carcinoma (Rechichi et al. 2010 ). These findings were also supported by the study of Bonatti et al. that also stated that T2-weighted images and DWI could replace the combination of T2-weighted images and contrast-enhanced T1-weighted images in the preoperative staging of endometrial carcinoma (Bonatti et al. 2015) .
Takeuchi and coworkers also reported an accuracy of 94 % for DWI and of 88 % for DCE-MR in the assessment of myometrial invasion (Takeuchi et al. 2009 ).
ADC maps have also shown to provide accurate measurement of the depth of myometrial invasion (Gallego et al. 2014 ).
Nonetheless, a recent meta-analysis assessing only nine studies showed that although DWI-MR has a slightly higher specificity in the diagnosis of myometrial invasion, DCE-MR and DWI-MR do not differ significantly in sensitivity and specificity in presurgical diagnosis of myometrial invasion (Andreano et al. 2014 ).
Stage II Disease
Stage II disease is characterized by cervical stromal invasion (Pecorelli 2009 ).
In the majority of cases, T2-weighted images are helpful in diagnosing cervical stromal invasion by depicting a heterogeneous hyperintense tumor disrupting the hypointense cervical stroma (Manfredi et al. 2005) .
Axial oblique plane of the cervix (perpendicular to the cervical canal) postcontrast injection 3D-reccaled echo fat-suppressed T1-weighted images in a late phase (≈80-240 s) are also very useful in assessing cervical stromal invasion, as they show the disruption of cervical enhancement by the tumor ( endometrial tumor is heterogeneous and shows both areas of hypointense and hyperintense signal relatively to the outer myometrium after administration of gadolinium in the equilibrium phase. This makes it difficult to assess myometrial invasion. Outer tumoral myometrial invasion in this thinned myometrium is better depicted in the diffusion-weighted image and in the respective ADC map (arrows)
2012; Seki et al. 2000) . Normal enhancement of the cervical epithelium is present in tumors that project into the endocervical canal but do not invade the cervical stroma (Fig. 18 ) Haldorsen and Salvesen 2012) . Sagittal T2-weighted image shows a voluminous endometrial tumor that prolapses in the cervical canal. The axial oblique plane of the cervix is very useful in detecting stromal invasion, especially after the administration of gadolinium in a late phase (4 min) (arrow) a b c Fig. 18 Endometrial cancer prolapsed into the endocervical canal (a) Axial oblique plane of the cervix (perpendicular to the cervical canal) T2-weighted image: (b) sagittal T2-weighted image; (c) sagittal postcontrast injection 3D-reccaled echo fat-suppressed T1-weighted images in the equilibrium phase (120 s). Both axial oblique and sagittal T2-weighted images raise the suspicion of cervical invasion. However, there is normal enhancement of the cervical epithelium without any disruption, which excludes stage II disease
Stage III Disease
Stage III disease is defined by local or regional spread of the tumor and it is subdivided into three substages (Pecorelli 2009 ). In stage IIIA endometrial cancer, the tumor invades the serosa or/and the adnexa (Figs. 19  and 20) .
Disruption of the serosal hypointense signal on T2-weighted images or loss of the enhancing myometrial outer margin on DCE-MR indicates serosal invasion (Fig. 19) Manfredi et al. 2005) .
The invasion of the ovaries may be due to direct extension via transmyometrial invasion or due to metastasis. Nodular foci in the adnexa are particularly frequent in type II endometrial cancer and in high-grade endometrioid carcinoma . DWI-MR is very useful in depicting these cases as well as pelvic peritoneal disease (Fig. 20) Sala et al. 2010; Shen et al. 2008) .
In stage IIIB disease, there is tumoral involvement of the parametria and/or the vagina by direct extension or by skip metastasis (Figs. 21, 22 and 23) (Pecorelli 2009 ). Images of the axial oblique plane of the cervix (perpendicular to the cervical canal) are very helpful in detecting parametrial invasion (Fig. 21) . Detection of parametrial invasion is particularly important so surgeons can avoid perform a simple hysterectomy and thus perform a more extensive resection .
In stage IIIC endometrial cancer there is lymph node involvement (III C1 if there are positive pelvic lymph nodes and III C2 if there are positive paraaortic lymph nodes) (Fig. 24) (Pecorelli 2009 ).
MR sensitivity for detecting tumoral lymph node involvement is mostly low (Haldorsen and Salvesen 2012) . The assessment of lymphadenopathies on MR imaging is still based on morphologic criteria (shortest axis diameter >10 mm) (Haldorsen and Salvesen 2012; Manfredi et al. 2004 ). DWI-MR helps detect lymph nodes, but there is a significant overlap with the ADC values of benign and malignant nodes (Nougaret et al. 2013; Nakai et al. 2008; Roy et al. 2010 ).
Stage IV Disease
Stage IV endometrial cancers are subdivided in two substages: stage IVA if there is invasion of For an endometrial tumor to be considered as stage IVA, a lesion transgressing the hypointense T2-signal of the muscularis propria of the bladder and/or of the bowel must be clearly seen, as well as disrupting the hyperintense signal of the mucosa (Figs. 25 and 26) . Moreover, tumoral enhancement within the lumen should also be present (Figs. 25 and 26) . This is particularly important in the differential diagnosis of bladder bullous edema (a sign of tumoral involvement of the bladder serosa and muscular layer, but not of the mucosa), since it is not considered stage IVA disease .
Although rare at presentation, distant hematogenous disease most commonly affects the liver, lungs, and bone ( Fig. 27) (Numazaki et al. 2009 ).
In type 2 endometrial cancer, and in highgrade endometrioid endometrial cancer, stage IVB disease may present as in ovarian cancers with peritoneal carcinomatosis Sala et al. 2013 ). 
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Recent Advances in Functional MR Imaging in Assessing Endometrial Carcinoma
In perfusion MR, repeated acquisitions of sequential images during the passage of gadolinium through the tumor are performed. Tumoral signal intensity versus time graphs and quantitative perfusion maps may be obtained, making it possible to evaluate microvascularity parameters (Haldorsen and Salvesen 2012) . The value of perfusion MR in assessing endometrial cancer is not yet established and validation studies are necessary to study its potential benefit. Haldorsen et al. suggested that DCE-MRI may offer new information about the histological subtype and clinical course of endometrial carcinoma (Haldorsen et al. 2013) . On the other hand, other studies regarding DCE-perfusion MR and tumor grading have shown contradictory results (Haldorsen et al. 2013; Ippolito et al. 2014a, b) . 
Therapeutic Approaches
Surgery
All medical operable patients with endometrial cancer should be considered for surgery (Koh et al. 2014) .
The standard surgical approach of endometrial cancer consists of total hysterectomy with bilateral salpingo-oophorectomy, assessment of the abdominal cavity with biopsies of suspicious peritoneal lesions, cytology of peritoneal washing, and at least excision of enlarged lymph nodes (Koh et al. 2014) .
Although, systematic pelvic and para-aortic lymphadenopathy is considered part of FIGO surgico-pathological staging, there is still no consensus if it should be performed in cases of treatment of stage I endometrial cancer (Koh et al. 2014; Colombo et al. 2013; Soliman et al. 2010) .
A randomized study has shown that in patients where systematic lymphadenectomy was performed, a higher rate of postoperative complications was detected with no improvement of disease-free and overall survival rates (Benedetti Panici et al. 2008) . The ASTEC surgical trial also concluded that pelvic lymphadenectomy in patients with early disease did not improve overall or recurrence-free survival (ASTEC study group et al. 2009 ). These two studies had important limitations and caution must be taken to avoid overinterpretation.
On the other hand, a large retrospective study, the SEPAL study, showed survival benefits in patients with intermediate (FIGO IA and IB, grade 3 endometrioid carcinoma; FIGO IB, grade 1 and 2 endometrioid carcinoma with lymphovascular space invasion; FIGO IC and II endometrioid carcinoma; any type of type 2 endometrial cancer) and high risk (FIGO III and IV endometrioid carcinoma) endometrial carcinoma when ; (e) ADC map. T2-weighted images show disruption of the hypointense signal of the bladder wall and mucosal invasion. There is tumoral enhancement within the lumen. The tumor shows also marked restricted diffusion, which can also be seen in the bladder lumen submitted to combined pelvic and para-aortic lymphadenectomy (Todo et al. 2010) .
Women with stage II should be considered for radical hysterectomy with bilateral salpingooophorectomy and pelvic and para-aortic lymphadenectomy (Colombo et al. 2013) .
In patients with a good performance status with advanced stage disease (FIGO stage III and IV), maximum debulking surgery of resettable tumors should be performed. Anterior and posterior pelvic exenteration can be considered for stage IVA disease as well as palliative surgery in patients with metastatic disease (Colombo et al. 2013) .
Women with serous, clear-cell carcinomas and carcinosarcomas should be submitted to the same surgical-pathological staging of ovarian cancer (Koh et al. 2014 ). Serous and clear-cell carcinomas can occur in atrophic endometrium and may present with distant disease even without myometrial invasion; therefore, omentectomy, diaphragmatic cytology or biopsy, and random peritoneal biopsies should be performed (Koh et al. 2014; Colombo et al. 2013 ). Pelvic and para-aortic lymphadenectomy is mandatory (Colombo et al. 2013 ).
Adjuvant Treatment
Radiation therapy is usually used in the adjuvant setting, in the form of external beam radiation therapy (EBRT) and vaginal brachytherapy (VBT). The purpose of adjuvant radiation therapy is to eliminate microscopic disease in the lymph nodes and in the central pelvic region, including the vaginal cuff; thus reducing the risk of recurrence.
According to the 2014 guidelines of the American Society for Radiation Oncology (ASTRO), patients with endometrioid carcinoma that do not require adjuvant radiotherapy (RT) are women with no residual disease in the hysterectomy specimen and patients with grade 1 or 2 endometrial cancer with no myometrial invasion or with <50 % of myometrial invasion, especially when no high risk features are present (Klopp et al. 2014) . Patients with grade 3 endometrioid carcinoma without myometrial invasion and patients with grade 1 or 2 cancer with <50 % of myometrial invasion and higher risk factors, such as being age >60 years and/or lymphovascular space invasion, can be adequately treated with or without VBT (Klopp et al. 2014 ). These guidelines also identify the patients with endometrioid cancer for whom vaginal cuff brachytherapy is as effective as pelvic radiation therapy and consequently should be preferred. These patients are women with grade 1 or 2 cancers with ≥50 % of myometrial invasion and women with grade 3 tumors with <50 % of myometrial invasion (Klopp et al. 2014) .
In order to decrease pelvic recurrence, the following women with early phase endometrial cancer should receive adjuvant EBRT: patients with stage I, grade 3 cancer with ≥50 % of myometrial invasion or patients with cervical stromal invasion; patients with stage I, grade 1 or 2 cancer, with ≥50 % of myometrial invasion and other risk factors such as being of age >60 years and/or lymphovascular space invasion (Klopp et al. 2014) .
If there is a negative prognostic factor, pelvic RT and/or chemotherapy should be performed for stage I and stage II disease (Colombo et al. 2013) .
In patients with stage III and IVA disease, external EBRT and adjuvant chemotherapy are justifiable options. These patients can be considered for concurrent chemoradiation followed by adjuvant chemotherapy (Klopp et al. 2014) .
If metastatic disease is present, chemotherapyradiotherapy can be performed for palliative treatment (Colombo et al. 2013) .
Patients with serous carcinomas, clear-cell carcinomas, and carcinosarcomas should be considered for platinum-based adjuvant chemotherapy with or without radiation therapy (Koh et al. 2014 ).
Fertility-Sparing Treatment
Fertility-sparing treatment with progestin hormonal therapy may be considered for women who express the desire to preserve fertility and have atypical endometrial hyperplasia or grade 1 endometrioid carcinoma without myometrial involvement in MR (Jafari Shobeiri et al. 2013; Kesterson and Fanning 2012; Colombo et al. 2016) . However, this is not the standard of care and the decision to proceed with conservative management is associated with several hazards. Risks include an inadequately staged and treated advanced endometrial cancer; the presence of a synchronous or meta-synchronous cancer; the presence of an inherited genetic predisposition; and the absence of standard medical management and surveillance (Kesterson and Fanning 2012) .
Follow-Up and Recurrent Endometrial Carcinoma
The majority of recurrences will occur within the first 3 years (80 %) ). However, only 15 % of patients will develop recurrent disease Magrina et al. 2011 ).
The recommended follow-up is a clinical and gynecological exam at 3-4 months intervals during the first 2 years and then every 6 months until 5 years (Colombo et al. 2013) .
During follow-up, radiological exams should only be performed if clinically indicated (Colombo et al. 2013) .
Most of endometrial cancer recurrences occur in the lymph nodes (46 %) and in the vaginal vault (42 %) (Sohaib et al. 2007 ). The peritoneum and lungs are also reported sites of recurrence, although less frequent (Sohaib et al. 2007 ).
MR imaging is very useful in diagnosing vaginal vault recurrences, which characteristically display the same signal characteristics as of those of the primary tumor . They tend to appear as a mass disrupting the low signal intensity of the vaginal vault . MR in these cases plays a role in defining surgical resectability of pelvic recurrences.
PET-CT has shown high sensitivity (93 %), specificity (93 %), and accuracy (93 %) in detecting recurrent disease (Kitajima et al. 2008) . However, more prospective larger studies must determine its role for routine screening (Salani et al. 2011) .
Treatment of Recurrence
Treatment of recurrence varies according to the site, to previous treatments, and to the initial stage of the disease.
Vaginal recurrence is the most common and the standard of treatment is EBRT plus VBP (Colombo et al. 2013) .
Central pelvic recurrence is usually treated with surgery and radiation therapy, whereas regional pelvic recurrence is treated with radiation therapy plus chemotherapy if possible (Colombo et al. 2013) .
Recurrent serous and clear-cell carcinomas should be treated with the same chemotherapeutic regimens of ovarian cancer (Colombo et al. 2013 ).
Prognosis
As stated previously, endometrial carcinoma generally has a good outcome. Prognostic factors include histological subtype; histological grade; tumor stage; depth of invasion; and lymphovascular space invasion (Colombo et al. 2013 ).
Reported 5-year survival rates for stage IA and IB are of 88 % and of 75 %, respectively. The prognosis of the different types of stage III substages differs significantly from one another, with estimated 5-year survival rates of 58 % for stage III C1 and of 47 % for stage III C2 . Stage IV disease 5-year survival is estimated at 15-17 % (American Cancer Society 2016).
The presence of lymph node metastasis, namely para-aortic, has shown to have a strong effect on prognosis (Todo et al. 2010) . Tumor grade, lymphovascular space involvement, and the depth of myometrial invasion have been reported as high risk factors for the tumoral involvement of lymph nodes (Patel et al. 2010) .
Invasion of the outer half of the myometrium is also strongly associated with a diminished 5-year survival rate (Patel et al. 2010; Amant et al. 2005) . Furthermore, it was demonstrated that patients with lymphovascular space involvement had an overall 5-year survival rate of 64 %, and on the other hand women without lymphovascular space involvement had an overall 5-year survival rate of 88 % (Colombo et al. 2013 ).
Conclusion
Magnetic resonance imaging is not considered in the International Federation of Gynaecology and Obstetrics staging system. However, it plays a relevant role in the preoperative staging of endometrial carcinomas, helping to define the best therapeutic approaches. Moreover, it is important in the diagnosis of treatment complications, in the surveillance of therapy response, and in the assessment of recurrent disease.
Functional MR techniques and specific MR sequence planes play an important role in preventing errors in endometrial cancer staging.
To help prevent diagnostic errors and in order to guide appropriate therapeutic management, radiologists should be aware of common magnetic resonance imaging endometrial appearances for all stages and the frequent mistakes in the assessment of endometrial cancer.
